Jessica Gajda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jessica Gajda has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Ari J. Firestone
Calico Life Sciences LLC, South San Francisco, California
22 shared publications - Fei Han
AbbVie (United States) 2 , North Chicago, Illinois
22 shared publications - Jonathan A. Hickson
AbbVie (United States) 2 , North Chicago, Illinois
22 shared publications - Aaron Boudreau
Calico Life Sciences LLC, South San Francisco, California
13 shared publications - Bryson D. Bennett
Calico Life Sciences LLC
13 shared publications - Celeste M. Sandoval
Calico Life Sciences LLC 1 , South San Francisco, CA
13 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Related to figure 2. (A) SPR sensorgrams of WRN WT and G729D treated with AC1 and AC2 (B) SPR sensorgram of WRN WT and D526_P530del treated with AC1 (C) Top: IGV browser window of whole exome sequencing variant calling file for AC1-resistant SW48 cells (D526_P530del) indicating a A->G mutation in the splice acceptor site before exon 13. Bottom: Sanger sequencing trace of a portion of the WRN helicase region indicating a mixed sequence of wildtype WRN and a 15 amino acid deletion. (D) Viability of WRN L528S/G729D SW48 cells or DMSO control cells treated with increasing doses of AC1 (left) and AC2 (right) normalized to DMSO treated cells measured with CTG after 3 days of treatment (n=3). (E) SPR sensorgram of WT WRN and L528S treated with AC1
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Related to figure 2. (A) SPR sensorgrams of WRN WT and G729D treated with AC1 and AC2 (B) SPR sensorgram of WRN WT and D526_P530del treated with AC1 (C) Top: IGV browser window of whole exome sequencing variant calling file for AC1-resistant SW48 cells (D526_P530del) indicating a A->G mutation in the splice acceptor site before exon 13. Bottom: Sanger sequencing trace of a portion of the WRN helicase region indicating a mixed sequence of wildtype WRN and a 15 amino acid deletion. (D) Viability of WRN L528S/G729D SW48 cells or DMSO control cells treated with increasing doses of AC1 (left) and AC2 (right) normalized to DMSO treated cells measured with CTG after 3 days of treatment (n=3). (E) SPR sensorgram of WT WRN and L528S treated with AC1
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Summary of cellular and biochemical IC50 values for each WRN mutation and inhibitor.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Summary of cellular and biochemical IC50 values for each WRN mutation and inhibitor.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Related to figure 4. (A) SPR sensorgram of WRN WT and F730L treated with AC1 (B) As in (A) with AC2 (C) As in (A) with C727R (D) SPR sensorgram of WRN WT and L528S treated with HRO761 (E) SPR sensorgram of WRN WT and I852F treated with AC1
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Related to figure 4. (A) SPR sensorgram of WRN WT and F730L treated with AC1 (B) As in (A) with AC2 (C) As in (A) with C727R (D) SPR sensorgram of WRN WT and L528S treated with HRO761 (E) SPR sensorgram of WRN WT and I852F treated with AC1
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
The Werner syndrome helicase (WRN) is a promising target for cancers with microsatellite instability (MSI), leading to the initiation of at least five phase I clinical trials. Acquired resistance is a substantial obstacle to obtaining lasting benefits from targeted therapies in oncology and may be particularly acute in the setting of mismatch repair–deficient (dMMR) tumors, which can sample increased fitness landscapes owing to a higher mutational burden. In this study, we characterized resistance mechanisms using the clinical candidate HRO761 and two novel inhibitors in MSI cell lines and xenograft models. We observed the rapid emergence of resistance both in vitro and in vivo, with sequencing revealing clustered mutations within the WRN helicase domain. Computational structural analyses indicated that these mutations either directly interfere with inhibitor binding or alter the protein conformation required for inhibitor engagement. Notably, although most mutations conferred broad resistance across all three compounds, we identified specific alterations (L528S, C727R, and F730L) that exhibited selectivity between chemical scaffolds. This chemotype-specific resistance profile suggests opportunities for developing next-generation inhibitors that retain activity against resistant variants and for implementing rational treatment strategies with existing inhibitors. Overall, our findings demonstrate that on-target resistance to WRN inhibitors emerges rapidly in dMMR backgrounds but also highlight potential approaches to overcome resistance, supporting the continued development of WRN-targeted therapies for MSI cancers.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
The Werner syndrome helicase (WRN) is a promising target for cancers with microsatellite instability (MSI), leading to the initiation of at least five phase I clinical trials. Acquired resistance is a substantial obstacle to obtaining lasting benefits from targeted therapies in oncology and may be particularly acute in the setting of mismatch repair–deficient (dMMR) tumors, which can sample increased fitness landscapes owing to a higher mutational burden. In this study, we characterized resistance mechanisms using the clinical candidate HRO761 and two novel inhibitors in MSI cell lines and xenograft models. We observed the rapid emergence of resistance both in vitro and in vivo, with sequencing revealing clustered mutations within the WRN helicase domain. Computational structural analyses indicated that these mutations either directly interfere with inhibitor binding or alter the protein conformation required for inhibitor engagement. Notably, although most mutations conferred broad resistance across all three compounds, we identified specific alterations (L528S, C727R, and F730L) that exhibited selectivity between chemical scaffolds. This chemotype-specific resistance profile suggests opportunities for developing next-generation inhibitors that retain activity against resistant variants and for implementing rational treatment strategies with existing inhibitors. Overall, our findings demonstrate that on-target resistance to WRN inhibitors emerges rapidly in dMMR backgrounds but also highlight potential approaches to overcome resistance, supporting the continued development of WRN-targeted therapies for MSI cancers.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Related to figure 1. (A) SPR sensorgrams of WT WRN treated with AC1 and AC2. (B) DNA unwinding activity of wildtype WRN in the presence of AC1 and AC2. (C) Molecular docking of AC1 bound to the WRN helicase region (D) Viability of WRN dependent and independent cell lines treated with AC1 (left) or AC2 (right) after 3 days inhibitor treatment measured with CTG n=2 (E) Fold change γH2A.X immunofluorescence staining normalized to DMSO control in WRN dependent and independent cells treated with AC1 (left) or AC2 (right) for 3 days. n=2 for all lines except SW620 n=1
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Related to figure 1. (A) SPR sensorgrams of WT WRN treated with AC1 and AC2. (B) DNA unwinding activity of wildtype WRN in the presence of AC1 and AC2. (C) Molecular docking of AC1 bound to the WRN helicase region (D) Viability of WRN dependent and independent cell lines treated with AC1 (left) or AC2 (right) after 3 days inhibitor treatment measured with CTG n=2 (E) Fold change γH2A.X immunofluorescence staining normalized to DMSO control in WRN dependent and independent cells treated with AC1 (left) or AC2 (right) for 3 days. n=2 for all lines except SW620 n=1
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Related to figure 3. (A) Mean tumor volume measurements (± SEM) in a HRO71-resistant SW48 xenograft model treated with vehicle or 120 mg/kg HRO761 (n = 10 mice per treatment group). (B) Mean body weight of mice corresponding to figure 3A (C) Mean body weight of mice corresponding to figure S3A (D) Heatmap of WES results for tumors treated with HRO761 in Fig 3A, B (E) Experiment level mutation results of HRO761 resistance experiments (F) Sanger sequencing results of HRO761 dose ramp-up resistance experiments (G) SPR sensorgram of WRN WT and G729D treated with HRO761 (H) As in G with C727R (I) As in G with F730L (J) As in G with D526_P530del
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
Related to figure 3. (A) Mean tumor volume measurements (± SEM) in a HRO71-resistant SW48 xenograft model treated with vehicle or 120 mg/kg HRO761 (n = 10 mice per treatment group). (B) Mean body weight of mice corresponding to figure 3A (C) Mean body weight of mice corresponding to figure S3A (D) Heatmap of WES results for tumors treated with HRO761 in Fig 3A, B (E) Experiment level mutation results of HRO761 resistance experiments (F) Sanger sequencing results of HRO761 dose ramp-up resistance experiments (G) SPR sensorgram of WRN WT and G729D treated with HRO761 (H) As in G with C727R (I) As in G with F730L (J) As in G with D526_P530del
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
DNA unwinding activity of WRN mutant proteins
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
DNA unwinding activity of WRN mutant proteins
- Open Access
- 6 March 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (8) , OF1-OF12
Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
The Werner syndrome helicase (WRN) is a promising target for cancers with microsatellite instability (MSI), leading to the initiation of at least five phase I clinical trials. Acquired resistance is a substantial obstacle to obtaining lasting benefits from targeted therapies in oncology and may be particularly acute in the setting of mismatch repair–deficient (dMMR) tumors, which can sample increased fitness landscapes owing to a higher mutational burden. In this study, we characterized resistance mechanisms using the clinical candidate HRO761 and two novel inhibitors in MSI cell lines and xenograft models. We observed the rapid emergence of resistance both in vitro and in vivo, with sequencing revealing clustered mutations within the WRN helicase domain. Computational structural analyses indicated that these mutations either directly interfere with inhibitor binding or alter the protein conformation required for inhibitor engagement. Notably, although most mutations conferred broad resistance across all three compounds, we identified specific alterations (L528S, C727R, and F730L) that exhibited selectivity between chemical scaffolds. This chemotype-specific resistance profile suggests opportunities for developing next-generation inhibitors that retain activity against resistant variants and for implementing rational treatment strategies with existing inhibitors. Overall, our findings demonstrate that on-target resistance to WRN inhibitors emerges rapidly in dMMR backgrounds but also highlight potential approaches to overcome resistance, supporting the continued development of WRN-targeted therapies for MSI cancers.
- 6 March 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (8) , OF1-OF12
Open AccessMicrosatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors
The Werner syndrome helicase (WRN) is a promising target for cancers with microsatellite instability (MSI), leading to the initiation of at least five phase I clinical trials. Acquired resistance is a substantial obstacle to obtaining lasting benefits from targeted therapies in oncology and may be particularly acute in the setting of mismatch repair–deficient (dMMR) tumors, which can sample increased fitness landscapes owing to a higher mutational burden. In this study, we characterized resistance mechanisms using the clinical candidate HRO761 and two novel inhibitors in MSI cell lines and xenograft models. We observed the rapid emergence of resistance both in vitro and in vivo, with sequencing revealing clustered mutations within the WRN helicase domain. Computational structural analyses indicated that these mutations either directly interfere with inhibitor binding or alter the protein conformation required for inhibitor engagement. Notably, although most mutations conferred broad resistance across all three compounds, we identified specific alterations (L528S, C727R, and F730L) that exhibited selectivity between chemical scaffolds. This chemotype-specific resistance profile suggests opportunities for developing next-generation inhibitors that retain activity against resistant variants and for implementing rational treatment strategies with existing inhibitors. Overall, our findings demonstrate that on-target resistance to WRN inhibitors emerges rapidly in dMMR backgrounds but also highlight potential approaches to overcome resistance, supporting the continued development of WRN-targeted therapies for MSI cancers.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer
Guide information for LNP studies
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer
Guide information for LNP studies